Dogwood Therapeutics Secures $100M Partnership for Antiviral Assets
Alpharetta, Georgia, USA – April 23, 2026 Dogwood Therapeutics announced a global development and commercialization partnership with PRIDCor Therapeutics...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Alpharetta, Georgia, USA – April 23, 2026 Dogwood Therapeutics announced a global development and commercialization partnership with PRIDCor Therapeutics...
SOUTH SAN FRANCISCO, Calif., April 16, 2026 Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop...
RAHWAY, N.J., USA — March 31, 2026 Merck & Co. has entered into a strategic antibody discovery collaboration with...
BOSTON & SOUTH SAN FRANCISCO, Calif., USA, April 1, 2026 Frontier Medicines has announced an exclusive global licensing agreement...
